Edesa Biotech Q1 FY2026 net loss $2.2M; progresses EB06 vitiligo Phase 2 prep

Edesa Biotech, Inc.

Net loss of $2.2M ($0.28/share) vs. $1.6M ($0.48/share) a year ago; operating expenses $2.3M.
Cash and equivalents $12.1M; working capital $12.0M at Dec 31, 2025.
EB06 (anti-CXCL10) manufacturing underway for Phase 2 vitiligo study; patient enrollment targeted mid-2026.
Paridiprubart Phase 3 ARDS data under subgroup analysis; plans to present at scientific conferences.
Participating in GVFS, BIO Europe Spring, ATS 2026 and other conferences March-May 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.